The present disclosure relates to antibody drug conjugates (ADC's) with auristatin E that binds to 191P4D12 protein and variants thereof. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in some cancers. The ADC's of provide a therapeutic composition for the treatment of cancer.